Development and Validation of Analytical Methods for the Determination of Some Dermatological Drugs Amaal Abdullah Al-Tahami

Total Page:16

File Type:pdf, Size:1020Kb

Development and Validation of Analytical Methods for the Determination of Some Dermatological Drugs Amaal Abdullah Al-Tahami Development and Validation of Analytical Methods for the Determination of Some Dermatological Drugs A Thesis Presented by Amaal Abdullah Al-Tahami B. Pharm. Sci. (1993) Faculty of Pharmacy, Sana’a University M. Pharm. Sci. (2001) Faculty of Pharmacy, Jordan University Submitted for The Degree of Doctor of Philosophy in Pharmaceutical Sciences (Pharmaceutical Chemistry) Supervised By Prof. Dr. Asmaa Ahmed El-Zaher Professor of Pharmaceutical Chemistry Faculty of Pharmacy Cairo University Ass. Prof. Dr. Ehab Farouk El-Kady Associate Professor of Pharmaceutical Chemistry Faculty of Pharmacy Cairo University Faculty of Pharmacy Cairo University 2018 1 Abstract: This thesis is concerned with the development of simple and accurate methods for the determination of some dermatological drugs, namely; betamethasone dipropionate, clioquinol, clobetasol propionate, diflucortolone valerate, econazole nitrate, fusidic acid, hydrocortisone, metronidazole benzoate, miconazole nitrate, mometasone furoate, salicylic acid and triamcinolone acetonide either alone or in combination with other drugs. Different methods have been introduced for determination of the analyzed drugs in their pure form, laboratory prepared mixture and in pharmaceutical dosage forms. 2 Introduction Dermatosis is a term that refers to diseases of the integumentary system. This classification includes everything on the surface of the body: skin, nails, and hair. Any condition affecting the skin could be categorized a dermatosis. Skin has several layers, including the epidermis, the dermis, and the subcutaneous tissue Figure 1. A dermatosis may involve changes in any or all of these skin layers[1]. Figure 1: Skin layers Some of the most common dermatological disorders: Table 1: some of the most common dermatological disorders Name Description [2] Causes [3] Oil glands in skin cause pimples Acne Bacteria and hormone and scarring Alopecia Hair loss around patches Autoimmune disorders areata Impetigo Skin infection Bacteria Keratosis Crusty pre-cancerous growths Sun damage The most serious form of skin Melanoma Genetic susceptibility cancer basal 3 Nails curve around the fingertips Nail due to low oxygen levels in the Various types of lung disease clubbing blood Several causes such as The fingernails become loose and Onycholysis (Trauma, infection, and skin separate from the nail bed disease) Characterized by patches of Psoriasis Autoimmune disorders abnormal skin Fungal infection of skin that Tinea Fungus leaves round marks Vitiligo White of patches of skin Autoimmune disorders Dermatological formulation Different dosage forms (e.g. creams, ointments, gels, pastes, suspensions, lotions, foams, sprays, aerosols, and solutions) containing special topical agents are directly applied to the malfunctioning skin to treat a specific disease or alleviate a condition. A unique aspect of dermatological pharmacology is the direct accessibility of the skin as a target organ for the diagnosis and treatment. Therapeutic agents can reach epidermal keratinocytes and immunocompetent cells in the epidermis and the underlying dermis that are involved in the pathogenesis of numerous cutaneous diseases. Topical agents can be applied directly to the skin but must penetrate into the tissue to achieve efficacy. Appropriate use of topical agents requires an appreciation of the factors that influence percutaneous absorption [4]. On the other hand, there are a lot of dermatological drugs used systemically involving several route of administration: oral, intramuscular (e.g., methotrexate, glucocorticoids), intravenous (e.g., immunoglobulin, alefacept) or subcutaneous (e.g., eflizumab, etanercept)[4]. Most common drugs for dermatological disorders: 1- Corticosteroids Corticosteroids have immunosuppressive and anti-inflammatory properties. They are used for treatment of psoriasis, eczema, contact dermatitis, and other skin conditions manifested by itching and inflammation [5]. Topical corticosteroids act by binding to a specific receptor in the cellular cytoplasm and modulating the transcription of multiple genes. This leads to the suppression of the production of inflammatory 4 substances such as prostaglandins and leukotrienes, and also inhibits the recruitment of inflammatory cells into the skin[6]. There are many topical steroids available, and they differ in potency and formulation Table 2. Table 2: Most commonly used corticosteroids for dermatological disorders: Generic Name Chemical Structure Alclometasone dipropionate Amcinonide Betamethasone dipropionate Clobetasol propionate Desonide Diflucortolone valerate Flucinolone acetonide 5 Fluticasone propionate Halobetasol propionate Hydrocortisone Mometasone furoate Triamcinolone acetonide 2- Antibacterial agents: Majority of skin infections are caused by Gram-positive bacteria, most commonly Staphylococcus aureus and group A β-hemolytic Streptococcus (GABHS). Some Gram-negative organisms and anaerobes may also cause pyogenic skin infections. Other organisms like Mycobacteria sp. and Treponema pallidum may also cause infections. Topical antibacterial agents may be useful in preventing infections in clean wounds, in the early treatment of infected dermatosis and wounds [5]. Each class of antibacterial drugs has a unique mode of action which is summarized in (inhibition of cell wall synthesis, inhibition of protein synthesis, inhibition of nucleic acid synthesis, alteration of cell membrane function or alteration of cell metabolism)[7]. Some topical anti-infectives contain corticosteroids in addition to antibiotics. There is no convincing evidence that topical corticosteroids inhibit the antibacterial effect of 6 antibiotics when the two are incorporated in the same preparation. In the treatment of secondarily infected dermatoses, which are usually colonized with streptococci, staphylococci, or both, combination therapy may prove superior to corticosteroid therapy alone. Antibiotic-corticosteroid combinations may be useful in treating diaper dermatitis and impetiginized eczema [8]. Table 3: Most commonly used antibacterial agents for dermatological disorders: Generic Name Chemical Structure Erythromycin Clindamycin Mupirocin Fusidic acid 3-Antifungal agents: The treatment of superficial fungal infections caused by dermatophytie fungi may be accomplished with topical antifungal agents Table 4. Topical antifungal corticosteroid fixed combinations have been introduced on the basis of providing more rapid symptomatic improvement than an antifungal agent alone. [4] Azole antifungal drugs inhibit the enzyme lanosterol 14 α-demethylase; the enzyme necessary to convert lanosterol to ergosterol. Depletion of ergosterol in fungal membrane disrupts the 7 structure and many functions of fungal membrane leading to inhibition of fungal growth [9]. Table 4: Most commonly used antifungal agents for dermatological disorders: Generic Name Chemical Structure Butenafine Clotrimazole Econazole nitrate HNO3 Fluconazole Ketoconazole Miconazole nitrate HNO3 8 4- Agents for acne: Acne, also known as acne vulgaris, is a long-term skin disease that occurs when hair follicles are clogged with dead skin cells and oil from the skin. It is characterized by blackheads or whiteheads, pimples, oily skin, and possible scarring. It primarily affects areas of the skin with a relatively high number of oil glands, including the face, upper part of the chest and back [10]. Many treatment options for acne are available, including lifestyle changes, medications, and medical procedures. Eating fewer simple carbohydrates such as sugar may help. Treatments applied directly to the affected skin, such as azelaic acid, benzoyl peroxide, and salicylic acid, are commonly used . Antibiotics and retinoids are available in formulations that are applied to the skin and taken by mouth for the treatment of acne Table 5. Isotretinoin pills are usually reserved for severe acne due to greater potential side effects [10]. Table 5: Most commonly used agents of acne for dermatological disorders: Generic Name Chemical Structure Azelaic acid Benzoyl peroxide Isotretinoin 5-Agents for pigmentation disorders Agents for pigmentation disorders include hydroquinone and methoxsalen, which are used for the treatment of hyperpigmented skin condition and vitiligo, respectively [5]. 9 Hydroquinone, monobenzone and mequinol (the monomethyl ether of hydroquinone) are used to reduce hyperpigmentation of the skin Table 6. Topical hydroquinone and mequinol usually result in temporary lightening, where a monobenzone causes irreversible depigmentation The mechanism of action of these compounds appears to involve inhibition of the enzyme tyrosinase, thus interfering with the bio-synthesis of melanin. In addition, monobenzone may be toxic to melanocytes, resulting in permanent loss of these cells. Some percutaneous absorption of these compounds takes place, because monobenzone may cause hypopigmentation at sites distant from the area of application. Both hydroquinone and monobenzone may cause local irritation. Allergic contact dermatitis to these compounds can occur. Prescription combinations of hydroquinone, fluocinolone acetonide, and retinoic acid (Tri-Luma®) and mequinol and retinoic acid (Solage®) are more effective than their individual components. Methoxsalen is a photoactive substance that stimulates melanocytes and is used as a repigmentation agent for patient with vitiligo [5]. Table 6: Most commonly used agents of pigmentation for dermatological disorders: Generic Name Chemical Structure Hydroquinone Mequinol Methoxsalen
Recommended publications
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Vitiligo Treatment
    ISSN 2320-5407 International Journal of Advanced Research (2014) Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH Depigmentation Therapy for Vitiligo: Results from a National Survey Dissertation submitted to Libyan International Medical University In partial fulfillment of the requirements For the award of the degree of Bachelor of Pharmacy BY Makpula Abdelaziz Tarhuni Aisha Ali Derbash Under The Guidance of Dr. Salma Bukhatwa 1 ISSN 2320-5407 International Journal of Advanced Research (2014) Declaration This is to certify that research work embodied in this thesis entitled "Depigmentation therapy of vitiligo: Results from a national survey" has been carried out by us under supervision of Dr. Salma Bukhatwa. Makpula Abdelaziz Tarhuni ................................................... Aisha Ali Derbash ...................................................... 2 ISSN 2320-5407 International Journal of Advanced Research (2014) Abstract Vitiligo is a chronicpigmentarydisorderthat causes the loss of skin color in blotches. Vitiligo happens because of destruction of melanocytes. Classification of vitiligo according to distribution of the lesions is of practical importance usually for assessing the prognosis of the disease. Repigmentation therapyfor vitiligo includes corticosteroids, topical and oral antioxidants, topical calcineurin inhibitors, phototherapy and laser therapy. Depigmentation therapy can be beneficial as alternative therapy for extensive vitiligo patients. Depigmentation therapyof vitiligo
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Topical Salicylic Acid and Lactic Acid Microemulsion
    Organic and Medicinal Chemistry International Journal ISSN 2474-7610 Research Article Organic & Medicinal Chem IJ Volume 2 Issue 3 - May 2017 DOI: 10.19080/OMCIJ.2017.02.555587 Copyright © All rights are reserved by Maher Aljamal Topical Salicylic acid and Lactic acid Microemulsion Maher Aljamal1,2*, Ibrahim Kayali2 and Mohammad Abul-Haj2 1BeitJala Pharmaceutical Company / Research and Development department, Palestine 2Department of Chemistry, Palestine, Al- Quds university, Israel Submission: April 26, 2017; Published: May 02, 2017 *Corresponding author: Maher Aljamal, BeitJala Pharmaceutical Company / Research and Development department, Al- Quds university, Palestine, Tel: ; Email: Abstract Microemulsionsare used to solubilizing and improve an active pharmaceutical ingredientssolubility and permeability, such as those for topical absorption availability. The objective of this study was to prepare a microemulsion liquid composed of 12% salicylic acid and 4% of lactic acid using castor oil, Tween 80, propylene glycol, ethyl alcohol and purified water. Using the low energy emulsification technique; four andpseudo transparent/translucent ternary phase diagrams microemulsion. were constructed The Resultsand studied indicate for ata leastclear, 75thermodynamic days under a titrationmicroemulsion method liquid using obtainedpurified waterin each (with of the or without propylene glycol), each phase diagram was investigated at 25°C, 37°C and 45°C. The phases include conventional emulsion, viscous using low concentration of Tween 80. It was suggested that microemulsions of 12% Salicylic acid and 4% Lactic acid could be a suitable vehicleconstructed for topical phase treatment diagrams ofat psoriasis, all temperatures scaly patches, of study. ichthyoses, Using propylene dandruff, glycol corns, as calluses, a co-surfactant, and wartson lead the to handsmore orstable feet.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Antifungal and Antibiotic Powders
    ANTIFUNGAL AND ANTIBIOTIC POWDERS Antifungals: Econazole Powder, Ketoconazole Powder, Nyamyc (nystatin) Powder, Nystop (nystatin) Powder Antibiotics: Mupirocin Powder, Tobramycin Powder, Vancomycin Powder RATIONALE FOR INCLUSION IN PA PROGRAM Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy powder products have the potential for misuse. Misuse of these powder products is quite common and it is important to inform patients about the possible complications due to overuse of these drugs. Regulatory Status FDA approved indication: Antifungal agents kill fungi or inhibit their growth. Antifungals that kill fungi are called fungicidal while those that inhibit their growth are called fungistatic. Antibiotics, or antimicrobials, are medications that destroy or slow down the growth of bacteria.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Vitiligo AHM
    Vitiligo AHM Clinical indication Any one of the following established methods for the treatment of Vitiligo is considered medically necessary : o Excimer laser (e.g., XTRAC, PhotoMedex, Radnor, PA; EX-308, Ra Medical Systems, Inc., Carlsbad, CA) o Narrow-band ultraviolet B (UVB) o Topical and oral psoralen photochemotherapy (PUVA) Note: Continued PUVA or narrow-band UVB therapy is not medically necessary unless there is significant follicular pigmentation after 6 months of therapy (8 to 10 treatments per month) o Topical and systemic corticosteroids Indications considered Not Medically Necessary Treatments for vitiligo are considered cosmetic if they do not affect the underlying condition and do not result in improved protection against skin cancer; specifically micropigmentation (tattooing) and depigmentation (with monobenzylether of hydroquinone/monobenzone) are considered cosmetic. The following treatments for the condition vitiligo are considered not medically necessary as there is a lack of evidence regarding the safety and effectiveness have not been established o Home phototherapy o Melanocyte transplantation/cultured and non-cultured cellular melanocyte keratinocyte transfer for the treatment of vitiligo o Vitamin D analogs (e.g., calcitriol and paricalcitol) o Tumor necrosis factor-alpha agents (e.g., adalimumab, etanercept, and infliximab) o Alpha-melanocyte stimulating hormone (e.g., afamelanotide) o Chimeric monoclonal antibody to CD20 (e.g., rituximab) o Autologous mini-punching grafting, blister roof grafting (suction epidermal blister grafting) and split thickness skin grafting AC-AEVITI082014 Page 1 of 5 Copyright 2016 No part of this document may be reproduced without permission ActiveHealth Management Medical Management Guidelines References: 1. Grimes PE. Diseases of hypopigmentation. In: Principles and Practice of Dermatology.
    [Show full text]
  • Laboratory Analysis Showed That Econazole and Miconazole
    laboratory analysis showed that econazole and Moorfields Eye Hospital miconazole had identical minimal inhibitory City Road London EC 1V 2PD, UK concentrations (0.25 mg/ml), and as econazole is less [email protected] toxic to corneal epithelium when used long-term,13 it was our agent of choice. If possible, pharmacological treatment should be Sir, combined with debridement and removal of necrotic tissue as this speeds recovery and improves final Conservative management of double penetrating ocular outcome.3 Antifungal treatment needs to be continued in injuries the long term after the infection has clinically resolved as Penetrating eye injuries can result in severe visual loss.1 fungal hyphae can persist in tissue several months after Double penetrating (perforating) injuries represent a obtaining negative microbiology swabs.14 separate group which generally have a poorer prognosis?-4 Various surgical options are available to The authors would like to thank Dr jane Leach of the deal with perforating eye injuries. Beneficial effects of microbiology department at Kingston Hospital for her help in vitrectomy in the management of perforating eye injuries the presentation of this case. have been reported,4 and scleral bucklingS,6 procedures with or without intravitreal gas injection also have a role References in the management of perforating eye injuries. We present two cases of double penetrating eye injuries 1. Rippon jW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia: Saunders, caused by slender sharp-tipped objects which were 1988. successfully managed conservatively. 2. McGuire TW, Bullock jO, Bullock jO jR, Elder BL, Funkhouser JW. Fungal endophthalmitis: an experimental study with a review of 17 human ocular cases.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]